The short version of PPAR delta fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
== Structure == Osteocytes have a stellate shape, approximately 7 micrometers deep and wide by 15 micrometers in length. The cell body varies in size from 5–20 micrometers in diameter and contain 40–60 cell processes per cell, with a cell to cell distance between 20–30 micrometers. A mature osteocyte contains a single nucleus that is located toward the vascular side and has one or two nucleoli and a membrane. The cell also exhibits a reduced size endoplasmic reticulum, Golgi apparatus and mitochondria, and cell processes that radiate largely towards the bone surfaces in circumferential lamellae, or towards a haversian canal and outer cement line typical of osteons in concentric lamellar bone. Osteocytes form an extensive lacunocanalicular network within the mineralized collagen type I matrix, with cell bodies residing within lacunae, and cell/dendritic processes within channels called canaliculi.
According to his father, the loan spells were the making of his son's career, while Tottenham's former Director of Football Damien Comolli, who was dismissed in October 2008, believes Townsend succeeded in spite of the way Tottenham handled him.
Apart from a detailed plotline and a few developers' screenshots, however, little information has been released about the game since 2005. Sparse updates have been published over the years at the company's official website and in a few specialized game magazines, and the final product is expected to be released via Steam. Drawing some comparisons to vaporware titles, Planet Half-Life announced (as a joke) on April 1, 2007 that They Hunger: Lost Souls had again been redesigned and was set for release as a Nintendo DS game. In November 2008, the developers of the Sven Co-op mod announced that they had been working with Black Widow Games to develop a co-op version of They Hunger, which was later released as an addon to be played in the mod in December 2008.
Sources: en.wikipedia.org
Light irradiance and wavelength Water absorption Carbon dioxide concentration Temperature. Total photosynthesis is limited by a range of environmental factors. These include the amount of light available, the amount of leaf area a plant has to capture light (shading by other plants is a major limitation of photosynthesis), the rate at which carbon dioxide can be supplied to the chloroplasts to support photosynthesis, the availability of water, and the availability of suitable temperatures for carrying out photosynthesis.
release of pituitary hormones synthesis of pituitary hormones release of stored pituitary hormones hyperplasia hypertrophy The anterior pituitary produces prolactin, GH, TSH, ACTH, FSH, and LH. Fifteen to 20 percent of corticotroph cells produce ACTH. The targets are the adrenal glands, adipocytes and melanocytes. Three to five percent of thyrotroph cells produce TSH. Ten to 15 percent are gonadotrophic and produce LH and FSH. Forty to 50 percent are somatotrophic and produce GH, in childhood in particular. Ten to 15 percent are lactotrophic and produce prolactin.
Atrophic gastritis is a process of chronic inflammation of the gastric mucosa of the stomach, leading to a loss of gastric glandular cells and their eventual replacement by intestinal and fibrous tissues. As a result, the stomach's secretion of essential substances such as hydrochloric acid, pepsin, and intrinsic factor is impaired, leading to digestive problems. The most common are pernicious anemia possibly leading to vitamin B12 deficiency; and malabsorption of iron, leading to iron deficiency anaemia. It can be caused by persistent infection with Helicobacter pylori, or can be autoimmune in origin. Those with autoimmune atrophic gastritis (Type A gastritis) are statistically more likely to develop gastric carcinoma (a form of stomach cancer), Hashimoto's thyroiditis, and achlorhydria. Type A gastritis primarily affects the fundus (body) of the stomach and is more common with pernicious anemia. Type B gastritis primarily affects the antrum, and is more common with H. pylori infection.
Sources: en.wikipedia.org
One of the SERRS was a "targeted nanoprobe functionalized with an anti-folate-receptor antibody (αFR-Ab) via a PEG-maleimide-succinimide and using the infrared dye IR780 as the Raman reporter, henceforth referred to as αFR-NP, and a nontargeted probe (nt-NP) coated with PEG5000-maleimide and featuring the IR140 infrared dye as the Raman reporter." These two different mixtures were injected into tumor bearing mice and healthy controlled mice. The mice were imaged with Bioluminescence (BLI) signal that produces light energy within an organism's body. They were also scanned with the Raman microscope in order to be able to see the correlation between the TAS3RS and the BLI map. TAS3RS did not show anything in the healthy mice, but was able to locate the tumor lesions in the infected mice and also able to create a TAS3RS map that could be used as guidance during surgery. TAS3RS shows to be promising in being able to combat ovarian and peritoneal cancer as it allows early detection with high accuracy. This technique can be administered locally, which is an advantage as it does not have to enter the bloodstream and therefore bypassing the toxicity concerns circulating nanoprobes. This technique is also more photostable than fluorochromes because SERRS nanoparticles cannot form from biomolecules and therefore there would not be any false positives in TAS3RS as there is in fluorescence imaging.
Krebs (1900–1981), German-British biochemist, Nobel Prize in Physiology or Medicine (1953)for work on metabolic cycles Harold Kroto (1939–2016), English chemist, 1996 Nobel Prize in Chemistry for discovery of fullerenes Richard Kuhn (1900–1967), 1938 Nobel Prize in Chemistry for work on carotenoids and vitamins Eugenia Kumacheva (PhD 1986), Ukrainian-Canadian chemist with work on fundamental and applied polymers science, nanotechnology, microfluidics, and interface chemistry Theodore Kuwana, (1931–2022), American chemist, founder of the field of spectroelectrochemistry
=== Biomechanical, sensory, and physiological properties of the body-wide fascia network === Chaudhry, H.; Huang, C.V.; Schleip, R.; Ji, Z.; Bukiet, B.; Findley, T. (2007). "Viscoelastic behavior of human fasciae under extension in manual therapy". Journal of Bodywork and Movement Therapies. 11 (2): 159–167. doi:10.1016/j.jbmt.2006.08.012. Schleip, R.; Duerselen, L.; Vleeming, A.; Naylor, I.L.; Lehmann-Horn, F.; Zorn, A.; Jaeger, H.; Klingler, W. (2012). "Strain hardening of fascia: Static stretching of dense fibrous connective tissues can induce a temporary stiffness increase accompanied by enhanced matrix hydration". Journal of Bodywork and Movement Therapies. 16 (1): 94–100. doi:10.1016/j.jbmt.2011.09.003. PMID 22196433. Schleip, R.; Mechsner, F.; Zorn, A.; Klingler, W. (2014). "The bodywide fascial network as a sensory organ for haptic perception". Journal of Motor Behavior. 46 (3): 191–193. doi:10.1080/00222895.2014.880306. PMID 24628059. Schleip, R.; Zorn, A.; Klingler, W. (2014). "Clinical relevance of fascial tissue and dysfunctions". Current Pain and Headache Reports. 18 (8): 439. doi:10.1007/s11916-014-0439-y. PMID 24962403.
== History == Founded in 1993 by Jack Owoc, Bang's parent company manufactured and distributed sports supplements and performance beverages under the brand name VPX. Other products distributed by Vital included Redline, Noo Fuzion, and Meltdown. In 2012, Vital created Bang, marketed as a low sugar carbonated energy drink and with the mission to make high-quality nutritional supplements backed by scientific research. In 2017, it was announced that Bang would offer a caffeine-free variant of the beverage, using beta-alanine in place of caffeine. In 2019, the company opened a manufacturing and distribution facility in Phoenix, Arizona, which operates alongside their facility in Pembroke Pines, Florida. In April 2020, PepsiCo entered into an exclusive distribution agreement with VPX to distribute Bang in the United States. On November 17, 2020, it gave PepsiCo a notice of termination; an emergency arbitrator ruled in December 2020 that Pepsi remained the exclusive distributor of Bang drinks until 2023. VPX resolved their disputes with PepsiCo and transitioned away from their distribution in June 2022. In August 2022, it was reported that Keurig Dr Pepper was in talks to purchase VPX; these talks fell apart shortly after the reports surfaced. On October 10, 2022, Bang's parent company filed for Chapter 11 bankruptcy protection. Three months after Owoc was removed and John DiDonato was named interim CEO of VPX, Monster Beverage reached an agreement for its purchase on June 28, 2023, this was completed one month later.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.